TODAY’S HEADLINES:
- San Diego’s Ocera raises $36M for gastrointestinal treatments (release)
- Antibody-drug maker Affimed pulls in €20M (release)
- GraftCath, venous catheter developer, gets $12M (VentureWire)
- Ranier Tech takes in £8M for spinal-disc replacements (release)
- NeuWave Medical pulls in $4.5M for microwave cancer treatment (Milwaukee J-S)
- Avalon Ventures closes $150M fund for biotech, wireless and Web media (release)
- Heptares Thera raises more seed funds for nervous-system disease (VentureWire)
- Essex Woodlands gets $800M for new life-science fund, aims for $1B (VentureWire)
- 5AM Ventures names Richard Ulevitch venture partner, promotes two others (release)
San Diego’s Ocera raises $36M for gastrointestinal treatments –Ocera Therapeutics, a San Diego specialty pharma working on treatments for Crohn’s disease and other gastrointestinal complaints, raised $35.5 million in a third funding round. Investors included Montagu Newhall Associates, InterWest Partners, AgeChem Venture Fund, Cross Creek, FinTech, CDIB BioScience, Domain Associates, Sofinnova Ventures, and Thomas McNerney & Partners.
Ocera, founded in 2005, licenses existing drugs from overseas pharmaceutical companies and runs them through clinical trials to win approval in the U.S. and other areas. Its lead candidate, AST-120, is currently marketed in Japan and Korea for the treatment of chronic kidney disease. Ocera, which acquired U.S. and European rights to the drug from Japan’s Kureha, is currently conducting late-stage, phase III trials of the drug in fistulizing Crohn’s disease, an autoimmune condition that can lead to the formation of channels called fistula that can run from the bowels to the skin and other organs.
AST-120 is composed of spherical carbon designed to absorb acids, toxins and other compounds thought to play a role in various diseases. Ocera is also testing the drug as a potential treatment for pouchitis, an inflammation of the small intestine in people who have undergone removal of some or all of the large intestine; irritable bowel syndrome; inflammatory liver enlargement; and drug-resistant gastrointestinal reflux disease. The company has now raised a total of $62 million in venture investment.
10:48 am
Acid Reflux Pill - Irritable bowel syndrome (functional bowel) said:
[...] Irritable bowel syndrome (functional bowel)HealthCentral.com - SYMPTOMS: Learn about the symptoms of acid reflux disease DRUGS: Common medications used to treat heartburn TREATMENT: Lifestyle changes, medication, and … Irritable bowel syndrome refers to a complex disorder of the lower intestinal tract … Drug interactions that can occur with azole antifungals (Pharmaceutical Journal) A patient who was stable taking carbamazepine for epilepsy, and ranitidine for gastro-oesophageal reflux, required treatment for oesophageal candidiasis following extended treatment with antibacterials. Oral therapy was considered appropriate for this patient. More U.S. Teeth Susceptible to Silent Enamel-eating Syndrome Cavities or not, your teeth could be in more trouble than you know because of a silent and destructive phenomenon called dental erosion. Life sciences briefing: Wednesday, Feb. 20, 2008 [...]
4:18 pm
Acid Reflux Pill - Mental stress: Hard On The Heart (Savannah Morning News) Q: said:
[...] Mental stress: Hard On The Heart (Savannah Morning News) Q: Hello Dr. C. My name is Michael. I am 43. I work for a bank in Savannah and have become progressively more worried about my health. I am under a great deal of stress at work. I try to exercise as often as I can, but it is becoming more difficult. I am somewhat overweight. I used to smoke, but I have been able to stop (for now.) I have had occasional chest pains, and I was told it is due to … Heartburn: Extinguishing the Fire — Lecture on March 21 Heartburn experienced persistently despite treatment and diet change, may develop into gastroesophageal reflux disease , or acid reflux. Life sciences briefing: Wednesday, Feb. 20, 2008 [...]